{"url":"https://newsforagent.com/news/2026-10-20/immune-boost-capital-orthrus-therapeutics-investment","markdown_url":"https://newsforagent.com/news/2026-10-20/immune-boost-capital-orthrus-therapeutics-investment.md","title":"Immune Boost Capital Invests in Orthrus Therapeutics","headline":"Immune Boost Capital Backs Orthrus Therapeutics Autoimmune Platform","description":"Immune Boost Capital invested in Orthrus Therapeutics, a Boston Children's Hospital spinout developing antigen-specific immune tolerance therapies for autoimmune disease.","section":"Funding","published_at":"2026-10-20T14:16:29+00:00","modified_at":"2026-10-20T14:16:29+00:00","author":"News Desk","key_takeaways":["Immune Boost Capital invested in Orthrus Therapeutics, a Boston Children's Hospital spinout developing antigen-specific immune tolerance therapies for autoimmune disease.","Dr. Sai Nandi, Immune Boost Capital's Founding Principal, will join the Orthrus Board of Directors as an observer and serve on the company's Scientific Advisory Board.","Immune Boost Capital provides $100K-$500K catalytic seed capital to early-stage founders and academic investigators developing autoimmune therapeutics, diagnostics, and enabling technologies."],"companies":[{"name":"Immune Boost Capital","is_primary":true,"profile_url":"https://akta.pro/company-profiles/00q61jp/immune-boost-capital","website":"https://immuneboostcapital.org"}],"source":{"publisher":"EIN Presswire","title":"Immune Boost Capital backs Orthrus Therapeutics in autoimmune disease push","url":"https://www.einnews.com/article/950967693/live"},"other_sources":[],"tags":["Funding","Immune Boost Capital"],"body_markdown":"[Immune Boost Capital](https://akta.pro/company-profiles/00q61jp/immune-boost-capital) has invested in Orthrus Therapeutics, a Boston Children's Hospital spinout developing antigen-specific immune tolerance therapies for autoimmune disease, with a focus on rheumatoid arthritis. [EIN Presswire](https://www.einnews.com/article/950967693/live) reported the investment on October 20, 2026. The deal adds a board observer and scientific adviser from IBC as both companies look to move beyond broad immunosuppression toward durable remission.\n\n## How the Orthrus Investment Works\n\nImmune Boost Capital, the venture investment arm of the Arthritis National Research Foundation, announced the investment in Orthrus Therapeutics. Orthrus is building an antigen-specific immune tolerance platform designed to address the root cause of autoimmune disease. The company's approach uses VHH-conjugates to selectively suppress disease-driving T cells. The platform also expands regulatory T cells, which help restore immune balance.\n\nOrthrus says the approach additionally targets pathogenic B cells to reduce disease-causing antibodies while preserving the patient's broader antibody repertoire. The company is developing VHH-drug conjugates, or VDCs, to restore antigen-specific immune tolerance, with an initial focus on T cell-driven autoimmune diseases. Orthrus says the platform has the potential to support immune reset, long-term remission or even cures.\n\nDr. Sai Nandi, Immune Boost Capital's Founding Principal, will join the Orthrus Board of Directors as an observer and serve on the company's Scientific Advisory Board. Immune Boost Capital said the funds will help Orthrus advance its technology and expand its platform across autoimmune indications. IBC operates as a philanthropic evergreen fund, with returns reinvested into future innovation. IBC also runs an IBC Venture Studio that works with founders and academic spinouts on strategy, operations and go-to-market planning.\n\n## Immune Boost Capital's Funding Model\n\nAccording to akta.pro [company records](https://akta.pro/company-data), Immune Boost Capital is a 501(c)(3) philanthropic venture fund that provides $100K-$500K catalytic seed capital to early-stage founders and academic investigators developing autoimmune therapeutics, diagnostics, and enabling technologies, recycling 100% of returns into the mission. The fund was founded in 2026 and is headquartered in Irvine, USA. Its leadership includes Sai Nandi as Founder and Managing Partner, Emily Stormoen as Director of Operations, Jeff Greenberg as Venture Partner and Board Chair, and Schalon Newton as Venture Partner.\n\n| Figure | Detail |\n|--------|--------|\n| Capital range | $100K-$500K |\n| Returns recycled | 100% |\n| Founded | 2026 |\n| Headquarters | Irvine, USA |\n\n## What Comes Next for Orthrus\n\nOrthrus will use the new capital to keep advancing its platform and build out programs for autoimmune disease. Dr. Nandi's board observer and advisory role gives IBC a formal channel to influence strategy as Orthrus develops. If the platform succeeds, Orthrus could move toward durable remission with fewer side effects and fewer treatment burdens for patients.\n","publisher":{"name":"News for Agent","url":"https://newsforagent.com"}}